| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035098142 |
| P356 | DOI | 10.1016/J.NURT.2006.11.005 |
| P932 | PMC publication ID | 7479698 |
| P698 | PubMed publication ID | 17199013 |
| P5875 | ResearchGate publication ID | 6601881 |
| P2093 | author name string | Steven C Schachter | |
| P2860 | cites work | Diverse mechanisms of antiepileptic drugs in the development pipeline | Q24675330 |
| Early identification of refractory epilepsy | Q28144133 | ||
| Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors | Q28249717 | ||
| Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group | Q28370856 | ||
| Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review | Q30703364 | ||
| Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...] | Q33202375 | ||
| Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...] | Q33202376 | ||
| Lamotrigine-associated rash: risk/benefit considerations in adults and children | Q33685953 | ||
| A review of the antiepileptic drug tiagabine. | Q33811462 | ||
| Pharmacokinetic profile of levetiracetam: toward ideal characteristics | Q33866334 | ||
| Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience | Q33961525 | ||
| Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics | Q33986368 | ||
| Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials | Q34083116 | ||
| Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs | Q34119454 | ||
| Pregabalin: a new anxiolytic | Q34187006 | ||
| Pharmacology and clinical experience with tiagabine | Q34240797 | ||
| On the association between valproate and polycystic ovary syndrome: a response and an alternative view | Q34301384 | ||
| Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). | Q34352314 | ||
| Pharmacokinetics of levetiracetam | Q34374263 | ||
| Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function | Q73267950 | ||
| Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy | Q73291417 | ||
| Zonisamide - induced urinary lithiasis in patients with intractable epilepsy | Q73851186 | ||
| Oxcarbazepine: a review | Q73876657 | ||
| Adding valproate to lamotrigine: a study of their pharmacokinetic interaction | Q74207281 | ||
| Felbamate: 1997 update | Q74523767 | ||
| Safety of tiagabine: summary of 53 trials | Q74643456 | ||
| Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients | Q77893190 | ||
| The AED (antiepileptic drug) pregnancy registry: a 6-year experience | Q80098015 | ||
| Hypohidrosis during topiramate treatment: a rare and reversible side effect | Q83221303 | ||
| Safety profile of levetiracetam | Q34374280 | ||
| Can anticonvulsant drug therapy "cure" epilepsy? | Q34387538 | ||
| Antiepileptic drug mechanisms of action | Q34394976 | ||
| Interactions between antiepileptic drugs and hormonal contraception | Q34595136 | ||
| Cognitive outcomes and predictive factors in epilepsy | Q34611383 | ||
| Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature | Q34654965 | ||
| New strategies for the identification of drugs to prevent the development or progression of epilepsy | Q34768804 | ||
| Some common issues in the use of antiepileptic drugs | Q34778740 | ||
| Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use | Q35124000 | ||
| Oligohydrosis and fever in pediatric patients treated with zonisamide | Q35138048 | ||
| Reproductive and metabolic disorders in women with epilepsy | Q35161328 | ||
| Management issues for women with epilepsy: neural tube defects and folic acid supplementation | Q35540886 | ||
| Guidelines for new antiepileptic drug evaluation | Q36363670 | ||
| Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors | Q36390884 | ||
| New antiepileptic drugs that are second generation to existing antiepileptic drugs | Q36491829 | ||
| Pharmacology and pharmacokinetics of fosphenytoin | Q40997759 | ||
| Parenteral antiepileptic/anticonvulsant drugs | Q40997765 | ||
| Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? | Q41078832 | ||
| Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs | Q41417980 | ||
| Epilepsy emergencies: the first seizure and status epilepticus | Q42053260 | ||
| Seizures during barbiturate withdrawal: relation to blood level | Q42215237 | ||
| Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients | Q42544838 | ||
| Exacerbation of juvenile myoclonic epilepsy with lamotrigine | Q43619542 | ||
| The regulation of serum sodium after replacing carbamazepine with oxcarbazepine | Q43650803 | ||
| Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality | Q43650811 | ||
| Valproate and the polycystic ovarian syndrome: final thoughts | Q43665509 | ||
| Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study | Q43906035 | ||
| Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women | Q44053294 | ||
| Lamotrigine clearance during pregnancy | Q44075693 | ||
| Variability of total phenytoin serum concentrations within elderly nursing home residents | Q44324818 | ||
| Major malformations in offspring of women with epilepsy | Q44324825 | ||
| The effects of adjunctive topiramate on cognitive function in patients with epilepsy | Q44339970 | ||
| Topiramate and word-finding difficulties in patients with epilepsy | Q44394580 | ||
| Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures | Q44456515 | ||
| Antiepileptic drug use of women with epilepsy and congenital malformations in offspring | Q46546783 | ||
| Treatment of epilepsy in adults: expert opinion, 2005. | Q46652012 | ||
| Improving quality of life beyond seizure control. | Q50959049 | ||
| Felbamate monotherapy has stimulant-like effects in patients with epilepsy. | Q52008842 | ||
| Congenital malformations due to antiepileptic drugs | Q61922624 | ||
| Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy | Q62376625 | ||
| Phenylethylmalonamide (PEMA). An important metabolite of primidone | Q69375985 | ||
| Valproic acid versus ethosuximide in the treatment of absence seizures | Q71583288 | ||
| The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs | Q71693807 | ||
| Relapse following discontinuation of antiepileptic drugs: a meta-analysis | Q72379343 | ||
| Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? | Q73172392 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 4-11 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Currently available antiepileptic drugs | |
| P478 | volume | 4 |
| Q28079632 | A systematic review of the effects of low-frequency repetitive transcranial magnetic stimulation on cognition |
| Q42009345 | Anticonvulsant effects of leptin in epilepsy |
| Q34299232 | Cannabidivarin is anticonvulsant in mouse and rat. |
| Q42095188 | Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism |
| Q24647214 | Current trends in the treatment of infantile spasms |
| Q33677979 | Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development |
| Q91810838 | Effects of GRM4, SCN2A and SCN3B polymorphisms on antiepileptic drugs responsiveness and epilepsy susceptibility |
| Q91991227 | Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment |
| Q24656333 | Levetiracetam in the treatment of epilepsy |
| Q42052272 | Novel therapeutic strategies for epilepsy--releasing the gene Genie |
| Q33415378 | Phenobarbitone-induced haematological abnormalities in idiopathic epileptic dogs: prevalence, risk factors, clinical presentation and outcome. |
| Q33900964 | Reduction in mortality and teratogenicity following simultaneous administration of folic acid and vitamin E with antiepileptic, antihypertensive and anti-allergic drugs |
| Q43424223 | Successful treatment of a dog with massive 5-fluorouracil toxicosis |
| Q37953107 | The NMDA receptor complex as a therapeutic target in epilepsy: a review |
Search more.